ChiCTR2400094967 版本V1.0 版本创建时间2024/12/31 09:20:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400094967 

最近更新日期:

Date of Last Refreshed on:

2024-12-31 09:19:10 

注册时间:

Date of Registration:

2024-12-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

探讨带状疱疹后神经痛和肠道菌群的关系

Public title:

Exploring the relationship between postherpetic neuralgia and gut microbiota

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探讨带状疱疹后神经痛和肠道菌群的关系

Scientific title:

Exploring the relationship between postherpetic neuralgia and gut microbiota

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陶熔 

研究负责人:

陶熔 

Applicant:

Tao Rong 

Study leader:

Tao Rong 

申请注册联系人电话:

Applicant telephone:

+86 18638185032

研究负责人电话:

Study leader's telephone:

+86 371 65580595

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wjsweet_2007@126.com

研究负责人电子邮件:

Study leader's E-mail:

13607649750@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市纬五路7号

研究负责人通讯地址:

河南省郑州市纬五路7号

Applicant address:

No. 7 Weiwu Road, Zhengzhou City, Henan Province

Study leader's address:

No. 7 Weiwu Road, Zhengzhou City, Henan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河南省人民医院

Applicant's institution:

Henan Provincial People's Hospital

研究负责人所在单位:

河南省人民医院

Affiliation of the Leader:

Henan Provincial People's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)伦审第(163)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

河南省人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Henan Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-14 00:00:00

伦理委员会联系人:

张辉

Contact Name of the ethic committee:

Hui Zhang

伦理委员会联系地址:

河南省郑州市纬五路7号

Contact Address of the ethic committee:

No. 7 Weiwu Road, Zhengzhou City, Henan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 371 87160680

伦理委员会联系人邮箱:

Contact email of the ethic committee:

hnsrmyyzh@126.com

研究实施负责(组长)单位:

河南省人民医院

Primary sponsor:

Henan Provincial People's Hospital

研究实施负责(组长)单位地址:

河南省郑州市纬五路7号

Primary sponsor's address:

No. 7 Weiwu Road, Zhengzhou City, Henan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

Country:

China

Province:

Henan

City:

单位(医院):

河南省人民医院

具体地址:

河南省郑州市纬五路7号

Institution
hospital:

Henan Provincial People's Hospital

Address:

No. 7 Weiwu Road, Zhengzhou City, Henan Province

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

Target disease:

Postherpetic neuralgia (PHN)

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本研究目的是探讨带状疱疹后神经痛(postherpetic neuralgia,PHN)和肠道菌群的关系,为寻找PHN发病的分子机制及药物治疗靶点提供新的见解与实验依据。  

Objectives of Study:

The purpose of this study is to explore the relationship between postherpetic neuralgia (PHN) and gut microbiota, in order to provide new insights and experimental evidence for the molecular mechanisms and drug treatment targets of PHN.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.病例组纳入标准:符合PHN诊断标准的住院患者;年龄18~80岁;带状疱疹病程>1月;疼痛评分(VAS评分)均大于或等于4分,患者自愿参与本研究,患者或家属签署知情同意书。
2.健康组纳入标准:年龄18~80岁;未患过带状疱疹;自愿参与本研究,患者或家属签署知情同意书。

Inclusion criteria

1.Inclusion criteria for case group: hospitalized patients who meet the diagnostic criteria for PHN; Age range of 18 to 80 years old; Herpes zoster course>1 month; Pain Scale (VAS) scores were all greater than or equal to 4 points, and patients voluntarily participated in this study; Patients or their families signed informed consent forms. 2.Inclusion criteria for the health group: age range of 18 to 80 years old; Have never suffered from herpes zoster; Voluntary participation in this study; Patients or their families signed informed consent forms.

排除标准:

1.病例组排除标准:不愿参与该实验,合并严重系统性疾病,如严重心脏病、严重肝、肾疾病、血液病等;合并精神心理疾病;合并癫痫史或癫痫家族史;有全身或局部感染,凝血功能异常等;认知功能障碍等;有其他不能配合治疗等的情况。
2.健康组排除标准:不愿参与该实验,合并糖尿病,合并高血压,合并严重系统性疾病,如严重心脏病、严重肝、肾疾病、血液病等;合并精神心理疾病;有其他不能配合治疗等的情况。

Exclusion criteria:

1.Exclusion criteria for the case group: unwillingness to participate in the experiment, combined with serious systemic diseases such as severe heart disease, severe liver and kidney disease, blood disease, etc; Merge mental and psychological disorders; Combining a history of epilepsy or a family history of epilepsy; Has systemic or local infections, abnormal coagulation function, etc; Cognitive impairment, etc; There are other situations where treatment cannot be coordinated. 2.Exclusion criteria for health group: unwilling to participate in the experiment, combined with diabetes, hypertension, and serious systemic diseases, such as serious heart disease, serious liver, kidney disease, and blood disease; Merge mental and psychological disorders; There are other situations where treatment cannot be coordinated.

研究实施时间:

Study execute time:

From 2024-12-01 00:00:00 To 2025-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-12-31 00:00:00 To 2025-08-31 00:00:00  

干预措施:

Interventions:

组别:

病例组

样本量:

35

Group:

Case group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

健康组

样本量:

35

Group:

Health group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

 

Country:

China 

Province:

Henan 

City:

 

单位(医院):

河南省人民医院 

单位级别:

三级甲等 

Institution
hospital:

Henan Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

quality of life

Type:

Secondary indicator

测量时间点:

入组后,治疗前

测量方法:

生活质量评估量表,36项简明量表

Measure time point of outcome:

After enrollment, before treatment

Measure method:

quality of life assessment, short form 36

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

Pain score

Type:

Secondary indicator

测量时间点:

入组后,治疗前

测量方法:

视觉模拟评分量表

Measure time point of outcome:

After enrollment, before treatment

Measure method:

visual analogue scale

指标中文名:

心理状态

指标类型:

次要指标

Outcome:

psychological state

Type:

Secondary indicator

测量时间点:

入组后,治疗前

测量方法:

汉密尔顿焦虑量表,汉密尔顿抑郁量表

Measure time point of outcome:

After enrollment, before treatment

Measure method:

Hamilton anxiety scale, Hamilton depression scale

指标中文名:

睡眠

指标类型:

次要指标

Outcome:

sleep

Type:

Secondary indicator

测量时间点:

入组后,治疗前

测量方法:

匹兹堡睡眠质量指数

Measure time point of outcome:

After enrollment, before treatment

Measure method:

Pittsburgh sleep quality index

指标中文名:

菌群种类

指标类型:

主要指标

Outcome:

Types of microbial communities

Type:

Primary indicator

测量时间点:

入组后,治疗前

测量方法:

高通量测序技术采用细菌16SrDNA扩增子测序的方法

Measure time point of outcome:

After enrollment, before treatment

Measure method:

High throughput sequencing technology uses bacterial 16S rDNA amplicon sequencing method

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-12-31 09:19:09